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A B S T R A C T
A combination of hypertonic saline and furosemide has been proposed as a new therapeutic approach for
treating acute decompensated heart failure (ADHF). The advantages of this combination have not only
been demonstrated in ADHF but also in refractory ascites due to liver cirrhosis. However, the therapeutic
effects of this regimen have never been evaluated in ADHF with overt diabetic nephropathy (ODN). Here,
we present an interesting case of a 35-year-old patient admitted to our hospital for ADHF with shortness
of breath and systemic edema, complicated with hypertension, type 2 diabetes, and ODN.
Echocardiography showed left ventricular enlargement and diffuse hypokinesis, with ejection fraction
of 33%. Urinary ﬁndings showed total proteinuria of 3597 mg/day during the ﬁrst day of hospitalization.
We initiated decongestion therapy with continuous infusion of hypertonic saline and furosemide. In
spite of increased diuresis, edema remained the same and serum albumin decreased from 2.7 g/dl to
2.0 g/dl, and proteinuria increased up to 7344 mg/day. The amount of proteinuria and serum albumin
level gradually recovered over time after cessation of the therapy. These data suggest that the
combination therapy worsens glomerular hypertension and ODN. Therefore, hypertonic saline and
furosemide combination therapy should not be recommended for patients with ODN.
<Learning objective: Hypertonic saline and low-dose furosemide combination therapy has been
proposed as a treatment option for ADHF, especially in refractory congestive heart failure cases.
Nevertheless, the efﬁcacy of this treatment in ADHF cases complicated with overt proteinuria is not fully
elucidated. This therapy may induce increment of proteinuria in these patients due to aggravation of
glomerular hypertension, and may be ineffective for decongestion or to treat edema.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Hypertonic saline and furosemide combination therapy has
been reported as an effective treatment for acute decompensated
heart failure (ADHF). This therapy was used mostly in cases of
diuretic resistance, or in cases of refractory heart failure [1]. This
therapy is also thought to be renoprotective since it preserved* Corresponding author at: Cardiovascular Division, Department of Internal
Medicine, Hyogo College of Medicine, 1-1 Mukogawa, Nishinomiya,
Hyogo 663-8501, Japan. Tel.: +81 798 45 6553; fax: +81 798 45 6551.
E-mail address: hirotani@hyo-med.ac.jp (S. Hirotani).
http://dx.doi.org/10.1016/j.jccase.2015.08.003
1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightrenal ﬁltration function, as assessed by a signiﬁcantly smaller
increase in serum creatinine levels during the hospital stay of
patients who were administered the combination therapy
compared to patients given furosemide alone [2].
Type 2 diabetes mellitus (T2DM) is commonly seen in heart
failure patients, who over a period of time develop overt diabetic
nephropathy (ODN) due to long-standing diabetes mellitus (DM),
complicated with hypertension, loss of renal function, peripheral
edema, overt proteinuria, and hypoalbuminemia. However, the
efﬁcacy of combined therapy of hypertonic saline and furosemide
in ADHF patients with associated ODN has never been validated.
This is a report showing a case of ADHF with associated ODN,
in which administration of hypertonic saline and low-doses reserved.
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preexisting nephritic state.
Case report
A 35-year-old male patient was referred to the cardiology
department of Hyogo College of Medicine due to dyspnea on
exertion for the previous month and systemic edema for the past
year. His body weight increased by 8 kg in the past 4 weeks. His
blood pressure was recorded as 130/90 mmHg, and heart rate was
99 heartbeats/min. Clinical examination showed rales over the
lower third of both lungs, raised jugular venous pressure, and
edema in both lower limb extremities. On cardiac auscultation, a
3rd heart sound was heard. He was diagnosed as having ADHF and
was admitted to our department for the treatment of ADHF in
November 2012. He had been previously diagnosed with T2DM,
hypertension, ODN (Stage 3, overt nephropathy) [3], and prolifer-
ative diabetic retinopathy, for which he had undergone laser
treatment twice before. On admission, his serum sodium was
144 mEq/L, serum albumin was 2.7 g/dl, serum creatinine was
1.64 mg/dl, and plasma B-type natriuretic peptide was 612 pg/ml.
Urinary ﬁnding showed total proteinuria of 3597 mg/day. A urine
protein to creatinine ratio, which was obtained 2 days prior to
admission in the outpatient department, was 8.045. Electrocardio-
gram showed regular sinus rhythm with complete right bundle
branch block, and P sinistrocardiale. Chest X-ray showed bilateral
pulmonary congestion with moderate pleural effusion. Transtho-
racic echocardiography showed enlargement of the left ventricle
(LV), diffuse hypokinesis of LV, and distension of inferior vena cava
(LV end diastolic diameter, 60 mm; ejection fraction, 33%;
diameter of inferior vena cava, 25 mm without respiratory
change). He was already on oral medication, which included a
diuretic (furosemide 20 mg/day), an angiotensin II receptor
blocker (candesartan 8 mg/day), and an angiotensin-converting
enzyme inhibitor (lisinopril 10 mg/day).
Continuous intravenous infusion of hypertonic saline (1.7%
solution of NaCl, 500 ml/day) in addition to 40 mg of furosemide
was initiated. Although the treatment increased diuresis and
slightly reduced body weight, neither his edema nor pleural
effusion improved. In order to decrease edema, the dose of
furosemide was increased up to 120 mg/day, but diuresis and body
weight remained the same. As we continued hypertonic saline and
furosemide combination therapy, the amount of proteinuria
increased from 3597 mg/day to 7344 mg/day, and serum albumin
level decreased from 2.7 g/dl to 2.0 g/dl (Table 1). We assumed
hypoalbuminemia was worsened by hypertonic saline and
furosemide combination therapy, via aggravation of glomerular
hypertension. After cessation of the combination therapy, the
amount of proteinuria decreased to 4480 mg/day and serum
albumin level gradually recovered from 2.0 mg/dl to 2.4 mg/dl
(Fig. 1). To increase diuresis and reduce edema, the patient wasTable 1 Time course of blood examination and urinary ﬁndings.
Hospital day 2 0 3 7 
Serum albumin (g/ml) 2.7 2.7 2.3 
BUN (mg/dl) 37 37 37 34 
Cre (g/dl) 1.83 1.64 1.64 1.77
Ccr 22.1 41.5 
Serum sodium (mEq/L) 142 144 143 144 
24 h-Up (mg/day) 3597 7344 
Up/Ucr 8.045 5.83
AST/ALT 27/21 21/16 17/14 
Hematocrit 37.5 36.2 35 28.4 
CRP 0.4 0.2 1.9 
Abbreviations: BUN, serum blood urea nitrogen level; Cre, serum creatinine level; Ccr, cre
to creatinine ratios.prescribed tolvaptan, a vasopressin type 2 receptor antagonist at
7.5 mg/day, and then the dose was increased up to 15 mg/day, and
a thiazide diuretic (trichlormethiazide 2 mg/day) was added. But
sufﬁcient urinary volume could not be obtained and body weight
slightly increased.
Discussion
We have previously reported the efﬁcacy of intravenous salt
supplementation with low-dose furosemide for treatment of ADHF
[4]. However, the therapy did not decrease edema or reduce body
weight in the ADHF patients complicated with ODN. On the
contrary, it increased proteinuria, and lowered serum albumin
level. This deterioration could be due to sodium loading that could
have increased the intraglomerular pressure, which is already
increased with hyperﬁltration in patients with ODN, leading to
aggravation of proteinuria and renal injury, rather than resolving
edema.
In early stages of diabetic nephropathy, primary renal
vasodilatation with a greater reduction in afferent relative to
efferent arteriolar resistance results in increased intraglomerular
pressure and glomerular hyperﬁltration. This induces segmental
glomerulosclerosis and causes nephron loss. At the same time,
glomerulosclerosis induces hyperﬁltration in the spared nephrons
as a compensatory response to nephron loss, in an attempt to
maintain glomerular ﬁltration rate (GFR), further adding to the
glomerular injury. In diabetic animal model, there is a correlation
between urine albumin excretion and intraglomerular pressure,
and therefore, intraglomerular hypertension in DM increases
protein leakage across glomerular capillaries [5].
Sodium loading increases renal plasma ﬂow (RPF) and GFR in
mild heart failure patients [6]. GFR is determined mainly by
ﬁltration pressure and ﬁltration coefﬁcient. Therefore, sodium
loading may increase intraglomerular pressure and proteinuria as
a result of intraglomerular hypertension. In this patient, sodium
loading may have directly worsened intraglomerular hypertension
and aggravated glomerular injury, both leading to increase in
proteinuria. Hyperﬁltration caused by intraglomerular hyperten-
sion generally increases GFR and the amount of protein in urine. In
this patient, however, hypertonic saline with furosemide therapy
also increased serum creatinine level concurrently with the
amount of protein in urine. Therefore, sodium loading may have
other effects on renal function, in addition to causing intraglo-
merular hypertension. In spontaneously hypertensive rats, dietary
salt loading demonstrated decreased RPF, increased renal vascular
resistance and serum creatinine concentration, and increased
proteinuria [7]. Increased proteinuria itself causes tubular injury
through multiple pathways. Tubular injury has a link with
reduction of RPF through increasing renal vascular resistance,
consequently increasing serum creatinine concentration (Fig. 2)
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Fig. 1.
Time course of serum albumin level, urinary volume, body weight, and chest X-ray. Although combination of hypertonic saline and furosemide increased urinary
volume and slightly reduced body weight, plural effusion remained the same. As we continued the combination therapy, serum albumin level decreased from
2.7 g/dl to 2.0 g/dl. After ceasing the combination therapy, serum albumin level recovered to 2.4 g/dl. In spite of adding other diuretics, sufﬁcient urinary volume
could not be obtained and body weight slightly increased. Then extracorporeal ultraﬁltration method (ECUM) was employed on the patient, and ﬁnally the edema
was controlled.
Fig. 2.
Proposed mechanisms through which hypertonic saline and
furosemide combination treatment worsened proteinuria.
Hypertonic saline increases the effective circulating volume, and
consequently increases the cardiac output, resulting in the increase of
renal blood ﬂow. Increased renal blood ﬂow by sodium supplement
worsens intraglomerular hypertension, and aggravates glomerular
injury, and increases the amount of proteinuria. Increased proteinuria
causes tubular injury, consequently resulting in the reduction of renal
blood ﬂow.
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proteinuria. Yet the mechanisms linking elevated protein excretion
and CHF are not well elucidated. Several mechanisms have been
proposed to explain albumin excretion, including activation of
neurohormonal factors, vascular dysfunction, systemic inﬂamma-
tion, altered renal hemodynamics, and glomerular and tubular
dysfunction. Furosemide itself can increase urinary protein
excretion [10]. The observed increase in proteinuria may be
partially due to furosemide. The patient, however, was admitted
for worsening of heart failure several more times. In the later
admission, the patient was treated only with high dose of
furosemide, and no relevant hypoalbuminemia occurred. There-
fore, it is reasonable to suppose that increase in proteinuria was
due to initiation of hypertonic saline, rather than worsening of CHF
or usage of furosemide.
DM causes a hypercatabolism syndrome and reduces skeletal
muscle mass, and renal hyperﬁltration. These two factors often
lead to overestimation of renal function in DM. In our previous
study, we enrolled patients whose estimated GFR (eGFR) was over
15 ml/min/1.73 m2, because our preparatory study showed that
eGFR  15 ml/min/1.73 m2 without hyponatremia was associated
with aggravation of volume overload [4]. Although this patient’s
eGFR was 40 ml/min/1.73 m2, associated renal injury might have
been severe. The overestimation of GFR in this particular patient
might also have led to wrong decongestion therapy selection.
In conclusion, this case strongly suggests that the combination
therapy of hypertonic saline with furosemide should be avoided in
patients with developed overt proteinuria. Overt proteinuria is
one of the hallmarks of intraglomerular hypertension, and
elevation of intraglomerular pressure by the combination therapy
may further increase the amount of proteinuria, and consequently
reduce RPF.
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